Drug intelligence / Profile preview

IMM-002 (Rapafusyn Pharmaceuticals)

Development stage: Preclinical
Lead developer: RapaFusyn Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

IMM-002 is a preclinical drug candidate being developed by RapaFusyn Pharmaceuticals for the treatment of immunological and inflammatory disorders. It is part of the company's proprietary RapaGlues™ platform, which utilizes rapamycin-based macrocycles to create molecular glues. These glues are designed to facilitate protein-protein interactions, acting either as degraders or as non-degrading modulators of target proteins. IMM-002 is currently in the hit identification phase of development.

Beyond the preview

Go deeper on IMM-002 (Rapafusyn Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMM-002 (Rapafusyn Pharmaceuticals).

Explore the full profile